Analysts Set Scholar Rock Holding Co. (NASDAQ:SRRK) Target Price at $26.43

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) have earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $26.43.

Several research firms have recently commented on SRRK. BMO Capital Markets upped their price objective on Scholar Rock from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Scholar Rock in a research note on Tuesday, June 25th. Finally, Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Scholar Rock in a research note on Thursday, August 8th.

Scholar Rock Stock Up 10.3 %

Shares of Scholar Rock stock opened at $9.39 on Thursday. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36. Scholar Rock has a twelve month low of $6.03 and a twelve month high of $21.17. The company has a market cap of $751.48 million, a price-to-earnings ratio of -4.49 and a beta of 0.82. The company’s 50 day moving average is $8.93 and its 200 day moving average is $11.23.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.01. During the same period in the previous year, the company earned ($0.47) earnings per share. Research analysts anticipate that Scholar Rock will post -2.39 EPS for the current year.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its holdings in shares of Scholar Rock by 30.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 394,138 shares of the company’s stock valued at $7,410,000 after acquiring an additional 91,754 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Scholar Rock by 95.5% in the 1st quarter. Jane Street Group LLC now owns 244,318 shares of the company’s stock worth $4,339,000 after purchasing an additional 119,363 shares during the period. Rafferty Asset Management LLC bought a new position in shares of Scholar Rock during the 4th quarter valued at approximately $2,025,000. Kennedy Capital Management LLC purchased a new stake in Scholar Rock during the 1st quarter valued at $4,900,000. Finally, Vanguard Group Inc. raised its holdings in Scholar Rock by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 2,969,534 shares of the company’s stock valued at $52,739,000 after buying an additional 114,550 shares during the period. Institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.